Next-Generation ADC Trials – Turning Complexity Into Execution

By Jozsef Palatka, M.D., Senior Vice President and Global Therapeutic Head for Oncology

Antibody-drug conjugates (ADCs) are among the most promising and complex therapies in oncology, creating new challenges for clinical development teams. As next-generation ADCs advance into increasingly targeted patient populations, sponsors must balance scientific rigor with operational feasibility to deliver efficient, high-quality trial execution.

Drawing on extensive experience supporting global ADC programs, this article highlights practical strategies for executing modern ADC trials—from reducing site burden and streamlining biomarker screening to improving patient access and managing complex safety requirements. It highlights the importance of designing protocols that reflect real-world site and patient needs, leveraging digital tools for real-time monitoring and building collaborative partnerships that enable faster decision-making" is closer to his close.

Learn how continuous visibility into safety signals, enrollment status and operational performance can help protect patients while accelerating development timelines. Ultimately, success in ADC development depends not only on innovative science, but on operational strategies that transform complexity into sustainable trial execution.